NCT01225874View on ClinicalTrials.gov

Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL

NACompletedINTERVENTIONAL
Enrollment

3,762

Participants

Timeline

Start Date

December 31, 1999

Primary Completion Date

March 31, 2006

Conditions
Leukemia
Interventions
DRUG

SC-PEG E. coli L-asparaginase

Given IM

DRUG

cytarabine

Given IT

DRUG

daunorubicin hydrochloride

Given IV

DRUG

dexamethasone

Given orally

DRUG

methotrexate

Given IT

DRUG

pegaspargase

Given IM

DRUG

prednisone

Given orally

DRUG

vincristine sulfate

Given IV

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK

NCT01225874 - Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL | Biotech Hunter | Biotech Hunter